Search

Search Constraints

You searched for: Author/Creator Lechowicz, Mary Jo

Search Results

1. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma. (7th August 2015)

2. A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Issue 1 (25th May 2012)

3. A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States. Issue 7 (2nd December 2016)

7. Clustering of cutaneous T‐cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. Issue 8 (14th January 2020)

8. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Issue 12 (December 2018)

9. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Issue 6 (10th December 2019)